Related references
Note: Only part of the references are listed.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Monitoring Response to Tyrosine Kinase Inhibitor Therapy, Mutational Analysis, and New Treatment Options in Chronic Myelogenous Leukemia
Jerald P. Radich
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome
Lotta Ohm et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
Dragana Milojkovic et al.
BLOOD (2012)
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
Joelle Guilhot et al.
BLOOD (2012)
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
Hagop Kantarjian et al.
CANCER (2012)
Tyrosine kinase inhibitors in acute and chronic leukemias
Maro Ohanian et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B. Hanfstein et al.
LEUKEMIA (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
Chronic Myeloid Leukemia: State of the Art in 2012
Carmen Fava et al.
CURRENT ONCOLOGY REPORTS (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
Neil P. Shah et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
